Identification of SUPT3H as a novel 8q24/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation

OPEN

Citation: Blood Cancer Journal (2015) 5, e301; doi:http://dx.doi.org/10.1038/bcj.2015.26

Web End =10.1038/bcj.2015.26 http://www.nature.com/bcj

Web End =www.nature.com/bcj

LETTER TO THE EDITOR

Identication of SUPT3H as a novel 8q24/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation

Blood Cancer Journal (2015) 5, e301; doi:http://dx.doi.org/10.1038/bcj.2015.26

Web End =10.1038/bcj.2015.26 ; published online 10 April 2015

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (previously referred as blastic natural killer cell leukemia/lymphoma or agranular CD4+/CD56+ hematodermic neoplasm) is a rare hematologic malignancy derived from the precursors of plasma-cytoid dendritic cells and is now classied as a rare subtype of acute myeloid leukemia according to the 2008 WHO classication.1 The disease is a clinically aggressive tumor with a high frequency of cutaneous and bone marrow (BM) involvement. Tumor cells express CD4, CD43, CD45RA and CD56, as well as the plasmacytoid dentritic cell-associated antigens CD123, BDCA-2/ CD303, TCL1 and CTLA1.

The pathogenesis of BPDCN is largely unknown. Previous genetic study reported that complex chromosomal aberrations, such as deletion of 5q, 12p, 13q, 6q, 15q or 9, were observed in most cases with BPDCN.2 A reciprocal chromosomal translocation, t(6;8)(p21;q24), was reported in four cases with BM inltration25 and it appears to be a recurrent cytogenetic abnormality in BPDCN. Here, we report the identication of SUPT3H at 6p21 as a novel non-immunoglobulin (Ig) partner gene of 8q24 translocation in a patient with BPDCN presenting t(6;8)(p21;q24).

The patient was an 81-year-old man who visited our hospital because of cervical lymphadenopathy and skin tumor. He was found to have pancytopenia with hemoglobin level of 7.9 g/dl, a white blood cell count of 3.2 109 /l and a platelet count of 46 109 /l. Serum LDH level was highly elevated to 12780 IU/l. Lymph node (LN) biopsy presented diffuse inltration of atypical cells. Results of ow cytometry and immunohistochemistry analysis revealed that tumor cells were positive for CD4, CD7 and CD56, but negative for other myeloid or lymphoid markers including CD3, CD8, CD20, CD21, TIA1, granzyme B or myeloperoxidase. On the basis of immunophenotypic ndings, he was diagnosed as BPDCN. BM was highly inltrated with tumor cells. He was admitted for chemotherapy, but died of respiratory failure after the development of intracranial hemorrhage.

The results of conventional chromosome analysis were as follows; 47,X,-Y t(6;8)(p21;q24),+add(7)(p11.2),+der(8)t(6;8),+20 [17/20], 46,XY [3/20] among LN cells; 48,X,-Y,t(6;8)(p21;q24),+add(7)(p11.2),+der(8)t(6;8),+20 [5/13], 49, idem,+mar1 [2/13], 49,idem, der(8)t(6;8),?t(9;15)(p22;q15),+mar1 [2/13], 46, XY [3/13] among BM cells (Figure 1a).

We postured the possible involvement of MYC in t(6;8)(p21;q24) translocation and performed uorescence in situ hybridization analysis using the 8q24 probe-LSI MYC Dual Color, Break Apart Rearrangement Probe, consisting of the SpectrumOrange-labeled 5 LSI MYC probe, which begins at 119 kb upstream of the 5 end of MYC and extends 266 kb toward the centromere, and the SpecrumGreen-labeled 3 LSI MYC probe, which starts approximately at 3 of MYC and extends 407 kb toward the telomere (Abbott Japan, Tokyo, Japan). The result showed the splitting of hybridization signals on translocated chromosomes, indicating that the 8q24 chromosomal break occurred within or around MYC

(Figure 1b). However, DNA rearrangement within MYC gene was not detected by long-distance inverse PCR method.6 Immunohistochemistry of biopsied LN, using anti-c-Myc (N-term) rabbit monoclonal antibody (Epitomics, CA, USA), presented high expression of MYC protein in nucleus of the tumor cells (Figure 1c).

To determine 8q24 partner gene, we searched the chimeric transcript using the 3 rapid amplication cDNA end method, as frequent rearrangements within PVT1 locus locating 57 kb 3 of

MYC were recently reported in multiple myeloma with 8q24 abnormality.7 Total RNA was extracted from the patients BM and LN cells and reverse-transcribed using a QT primer (5-TGAGCAGA

GTGACGAGGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTT-3). cDNA was amplied with a specic primer, PVT1-F (5-CTGTGACCTGTGG AGACACGG-3), which corresponds to chromosome 8 sequence (nucleotides 128847191 to 128847211 of the reported genomic sequence: NCBI Reference Sequence NC_018919.2) and universal primer Q0 (5-CCAGTGAGCGAGTGACG-3). An aliquot of this reaction product was further amplied using PVT1-F and semi-nested universal primer Q1 (5-GAGGACTCGAGCTCAAGC-3).

Abnormal products were amplied from the patients LN and BM samples. The result of sequence of PCR products revealed that chromosome 8 sequence (previously referred as PVT1 exon 1) was fused to exon 3 of SUPT3H (suppressor of Ty 3 homolog (Saccharomyces cerevisiae)), which had been assigned to chromo-some 6p21,8 indicating the 6p21 chromosomal breakpoint was located within SUPT3H gene (Figure 2a).

The formation of the chimeric transcript was ascertained by RT-PCR analysis using PVT1-F and a primer from SUPT3H exon 7 (5-CCATACTGCTGCAGTCCAACC-3) (Figures 2b and c). Sequencing of the PCR product revealed that the SUPT3H part corresponded to type 1 transcript of the gene. Reciprocal transcript was not detected by RT-PCR. SUPT3H was also expressed from untranslocated allele in the patients tumor cells as shown by RT-PCR using SUPT3H exon 2 (5-AGCTAGTCCAATGTCTACTGC-3)

and exon 7 primers (Figures 2b and c).

Translation initiation site of SUPT3H was located at 5 side from the chromosome 6 breakpoint and an open reading frame, which started from chromosome 8 and fused in frame to SUPT3H, was generated in the chimeric transcript. The predicted product was truncated by 17 amino acids at N-terminus when compared with the wild-type SUPT3H protein.

SUPT3H is a TATA-binding protein-associated factors (TAF)-associated protein that composes of the human histone acetyl transferase STAGA complex (SPT3-TAF9-GCN5-acetylase)9,10 and is ubiquitously expressed in all tissues. Recently, a possible association between variation (interstitial duplication) in this gene and 46, XY gonadal dysgenesis was suggested,11 but, to our knowledge, its involvement in chromosomal translocation has not been reported so far.

The 8q24/MYC chromosomal translocations with Ig gene loci are the major genetic aberrations in Burkitts lymphoma. Recently, occasional occurrence of 8q24 rearrangements with non-Ig partners in B-cell lymphoma and multiple myeloma was reported.6,7 In myeloid tumor, ve cases with acute myeloid

Letter to the Editor

2

Figure 1. (a) G-banded karyogram of the patients BM cells. Arrows indicate the aberrant chromosomes. (b) Fluorescence in situ hybridization analysis of BM cells using Spectrum Orange-labeled 5 LSI MYC and Spectrum Green-labeled 3 LSI MYC probes. Normal chromosome 8 is shown by fusion of the two probes (a yellow arrow). Derivative 6 and 8 chromosomes are indicated by green and red arrows. (c) Immunohistochemistry of biopsied LN using anti-MYC antibody. MYC was highly expressed in nucleus of tumor cells.

Figure 2. (a) Partial nucleotide and deduced amino acid sequence around the junction of the fusion transcript. (b) Schematic representation of the fusion transcript. Horizontal arrows indicate primers used in RT-PCR. Triangles indicate translation initiation sites. (c) RT-PCR analysis, detecting the fusion and the normal SUPT3H transcripts. Lanes 1, 2 and 3 indicate peripheral mononuclear cells from a normal individual, the patients LN and BM cells, respectively.

leukemia exhibiting t(8;14)(q24;q32) chromosomal translocation were reported, previously.1115 In one of them, uorescence in situ hybridization analysis revealed an atypical 8q24 rearrangement without involvement of Ig heavy chain gene at 14q32 or MYC

overexpression, suggesting that the rare t(8;14) occurring in AML may differ molecularly from that observed in B-cell tumor.14 To our knowledge, our case is the rst instance of myeloid malignancy associated with 8q24 chromosomal translocation affecting MYC.

Blood Cancer Journal

Letter to the Editor

3

In our case, it was not determined whether or not the truncated SUPTH3H protein from the chimeric transcript was expressed in tumor cells or the structural alteration of the protein contributed to the cellular transformation. Thus, signicance of the formation PVT1-SUPT3H chimeric gene remains unknown and the overexpression of MYC by ectopic promoter on chromosome 6 may be essential to tumor genesis. However, our results indicate that 8q24 translocation may exert as a molecular pathogenesis in non-lymphoid hemato-logic neoplasms. Further investigation is needed to clarify the role of the chromosomal aberration in pathogenesis of BPDCN.

CONFLICT OF INTEREST

The authors declare no conict of interest.

Y Nakamura1, H Kayano2, E Kakegawa1, H Miyazaki2, T Nagai2, Y Uchida1, Y Ito1, N Wakimoto1, S Mori1 and M Bessho1

1Department of Hematology, Saitama Medical University, Saitama, Japan and

2Department of Pathology, Saitama Medical University, Saitama, Japan E-mail: mailto:[email protected]

Web End [email protected]

REFERENCES

1 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classication of Tumours of Haematopoetic and Lymphoid tissues. IARC: Lyon, 2008.

2 Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J et al. CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood 2002; 99: 41544159.

3 Momoi A, Toba K, Kawai K, Tsuchiyama J, Suzuki N, Yano T et al. Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases. Leuk Res 2002; 26: 693698.

4 Takiuchi Y, Maruoka H, Aoki K, Kato A, Ono Y, Nagano S et al. Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion: a borderline case between acute monocytic leukemia. J Clin Exp Hematopathol 2012; 52: 107111.

5 Fu Y, Fesler M, Mahmud G, Bernreuter K, Jia D, Batanian JR. Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms. Cancer Genet 2013; 206: 293298.

6 Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel M-N et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia 2007; 21: 515523.

7 Nagoshi H, Taki T, Hanamura I, Nitta M, Otsuki T, Nishida K et al. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res 2012; 72: 49544962.

8 Yu J, Madison JM, Mundlos S, Winston F, Olsen BR. Characterization of a human homologue of the Saccharomyces cerevisiae transcription factor Spt3 (SUPT3H). Genomics 1998; 53: 9096.

9 Ogryzko VV, Kotani T, Zhang X, Schiltz RL, Howard T, Yang X-J et al. Histone-like TAFs within the PCAF histone acetylase complex. Cell 1998; 94: 3544.

10 Martinez E, Kundu TK, Fu J, Roeder RG. A human SPT3-TAFII31-GCN5-L acetylase complex distinct from transcription factor IID. J Biol Chem 1998; 273: 2378123785.

11 Norling A, Hirschberg AL, Iwarsson E, Persson B, Wedell A, Barbaro M. Novel candidate genes for 46,XY gonadal dysgenesis identied by a customized 1 M array-CGH platform. Eur J Med Genet 2013; 56: 661668.

12 Sol F, Caballn MR, Coll MD, Woessner S, Besses C, Sans-Sabrafen J et al. Cytogenetic studies in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1992; 60: 117124.

13 Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA. Minimally differentiated acute nonlymphocytic leukemia: A distinct entity. Blood 1987; 70: 14001406.

14 Hoppman-Chancy NL, Cherry D, Holladay C, Yuhas J, Wang R, Velagaleti G. Identication of a patient with 7q32 deletion-associated acute myeloid leukemia and an incidental t(8;14). Cancer Genet Cytogenet 2010; 197: 179184.

15 Walker A, Mrzek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ et al. New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes; Cancer and Leukemia Group B 8461. Genes Chromosomes Cancer 2013; 52: 385401.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the articles Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Web End =http://creativecommons.org/licenses/ http://creativecommons.org/licenses/by/4.0/

Web End =by/4.0/

Blood Cancer Journal